Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LESLIE BRYAN FORGOSH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154305738
CMS profile
278624
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,013.54

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $890.71 3
Food and Beverage $122.83 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $1,013.54 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LESLIE BRYAN FORGOSH

NPI 1154305738 · CMS profile ID 278624

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154305738?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $1,013.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $115.0007/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226917780 CMS
Amgen Inc. $122.8307/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228270479 CMS
Amgen Inc. $187.4907/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226889784 CMS
Amgen Inc. $588.2207/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226924734 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.62 2
PY2020 $13.55 1
PY2022 $3,264.08 18
PY2023 $2,534.72 16
PY2024 $1,618.47 10
PY2025 $1,013.54 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,031.09 11
PY2025 Principal investigator $1,145,528.44 27
PY2024 Principal investigator $1,362,432.04 31
PY2023 Recipient $140.82 1
PY2023 Principal investigator $1,104,464.55 33
PY2022 Recipient $3,197.00 1
PY2022 Principal investigator $739,768.96 53
PY2021 Recipient $4,441.01 1
PY2021 Principal investigator $667,326.41 59
PY2020 Recipient $6,717.97 2
PY2020 Principal investigator $475,435.63 71
PY2019 Principal investigator $661,892.22 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $70.00 12/23/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117579
Recipient Regeneron Pharmaceuticals, Inc. $71.63 12/23/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117581
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,450.00 12/15/2025 Covered Recipient Teaching Hospital
Healtheast St Josephs Hospital
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190297208
Recipient Regeneron Pharmaceuticals, Inc. $339.78 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117565
Recipient Regeneron Pharmaceuticals, Inc. $609.76 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117567
Recipient Regeneron Pharmaceuticals, Inc. $89.89 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117569
Recipient Regeneron Pharmaceuticals, Inc. $41.49 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117571
Recipient Regeneron Pharmaceuticals, Inc. $110.63 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117573
Recipient Regeneron Pharmaceuticals, Inc. $41.49 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117575
Recipient Regeneron Pharmaceuticals, Inc. $88.50 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117577
Recipient Regeneron Pharmaceuticals, Inc. $131.30 12/05/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117563
Principal investigator 1 Boston Scientific Corporation $4,201.40 11/18/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
LUX-DX TRENDS No dispute reported 06/30/2026 1207572519
Principal investigator 1 Janssen Research & Development, LLC $3,330.00 11/13/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175235062
Recipient Regeneron Pharmaceuticals, Inc. $436.62 11/07/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184117561
Principal investigator 1 Amgen Inc. $2,454.42 10/08/2025 Non-covered Recipient Entity
M HEALTH FAIRVIEW ST. JOHN'S HOSPITAL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246643727
Principal investigator 1 Amgen Inc. $2,121.05 10/08/2025 Non-covered Recipient Entity
ST JOHNS HOSPITAL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246648613
Principal investigator 1 Eli Lilly and Company $312.00 09/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF MINNESOTA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187888766
Principal investigator 1 Amgen Inc. $72,875.00 09/23/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246637806
Principal investigator 1 Amgen Inc. $49,275.00 09/20/2025 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246642154
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,537.56 09/15/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309868
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,385.00 09/02/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190294637
Principal investigator 1 Novartis Pharmaceuticals Corporation $80,134.98 08/19/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309862
Principal investigator 1 Amgen Inc. $16,953.87 07/31/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246641345
Principal investigator 1 Amgen Inc. $34,772.12 07/20/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641347
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,178.00 04/30/2025 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1225406022
Principal investigator 1 Amgen Inc. $90,767.00 04/24/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246637804
Principal investigator 1 AstraZeneca Pharmaceuticals LP $89,825.28 02/21/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185540029
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,958.60 02/20/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308082
Principal investigator 1 Novartis Pharmaceuticals Corporation $288,090.60 02/17/2025 Covered Recipient Teaching Hospital
Healtheast St Josephs Hospital
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190294584
Principal investigator 1 Novartis Pharmaceuticals Corporation $51,543.44 02/04/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190308080
Principal investigator 1 Eli Lilly and Company $2,601.59 01/27/2025 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187883200
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,404.18 01/27/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309864
Principal investigator 1 Eli Lilly and Company $44,460.50 01/21/2025 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880195
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 01/17/2025 Covered Recipient Teaching Hospital
University Of Minnesota Medical Ctr
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175234836
Principal investigator 1 Novartis Pharmaceuticals Corporation $369.41 01/15/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309870
Principal investigator 1 Amgen Inc. $57,787.04 01/14/2025 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246641343
Principal investigator 1 Eli Lilly and Company $116,082.00 01/07/2025 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187881396
Principal investigator 1 Amgen Inc. $36,658.40 01/02/2025 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246642149